Compare RBCAA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | TRVI |
|---|---|---|
| Founded | 1974 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1998 | 2019 |
| Metric | RBCAA | TRVI |
|---|---|---|
| Price | $74.21 | $13.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $21.55 |
| AVG Volume (30 Days) | 73.8K | ★ 1.2M |
| Earning Date | 01-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $417,495,000.00 | N/A |
| Revenue This Year | $3.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $95.69 | ★ N/A |
| Revenue Growth | ★ 8.50 | N/A |
| 52 Week Low | $61.62 | $5.38 |
| 52 Week High | $78.00 | $14.39 |
| Indicator | RBCAA | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 64.91 | 70.29 |
| Support Level | $67.08 | $10.07 |
| Resistance Level | $75.91 | N/A |
| Average True Range (ATR) | 1.80 | 0.90 |
| MACD | 0.53 | 0.23 |
| Stochastic Oscillator | 83.45 | 98.30 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.